|Bid||136.110 x 200|
|Ask||136.230 x 100|
|Day's Range||134.390 - 136.735|
|52 Week Range||95.140 - 137.000|
|PE Ratio (TTM)||116.44|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A Relative Strength Rating upgrade for Glaukos shows improving technical performance. Will it continue?
Abiomed Inc. (ABMD), a leading developer, manufacturer and marketer of medical products, reported fourth-quarter fiscal 2017 earnings of 33 cents per share, which were in line with the Zacks Consensus Estimate.
Q4 2017 Abiomed Inc Earnings Call